Thomas Ichim, President and Chief Scientific Officer at Immorta Bio, shared on X:
“Nice to see my patents are validated.
What if cancer immunotherapy fails partly because tumors release soluble immune suppressors into the bloodstream? A 2025 phase I melanoma trial tested plasma exchange to remove soluble PD-L1 before immunotherapy rechallenge.
A fascinating strategy for reversing resistance.”
Title: Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial.
Authors: Jacob J. Orme, Henan Zhang, Prashanth Lingamaneni, Yohan Kim, Roxane Lavoie, Maddy Dorr, Paul Dizona, Jacob Hirdler, Elizabeth A. Bering, Joanina K. Gicobi, Michelle Hsu, Heather Dale, Daniel S. Childs, Lisa A. Kottschade, Robert R. McWilliams, Matthew S. Block, Aaron S. Mansfield, Svetomir N. Markovic, Ken Olivier, Dawn Owen, Scott Lester, Daniel Ma, Roxana S. Dronca, Haidong Dong, Fabrice Lucien, Annie T. Packard, Jeffrey L. Winters, Sean S. Park.
You can also read: PD-L1 Alone Is Not Enough: Why It Fails to Predict Immunotherapy Response in NSCLC.
